Status:
RECRUITING
Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination
Lead Sponsor:
University Medical Centre Ljubljana
Collaborating Sponsors:
MSD Pharmaceuticals LLC
Conditions:
Cervical Cancer Screening
Vaccination Uptake
Eligibility:
FEMALE
Up to 35 years
Phase:
NA
Brief Summary
Cervical cancer (CC), primarily caused by persistent infection with high-risk human papillomavirus (HPV) types, remains a significant public health issue. Despite the availability of prophylactic HPV ...
Eligibility Criteria
Inclusion
- regular cervical smear (CS) every 3 years after a previously normal CS result, first CS at entry into the ZORA screening program, second CS one year after entering the ZORA screening program following a previously normal first CS, control CS after a pathological cytological result or after a non-neoplastic cytological result or after conization or laser vaporization of the cervix, and curative CS due to signs or pathological clinical findings
Exclusion
- pregnancy at the time of the gynecological examination, menstrual bleeding at the time of the gynecological examination, inflammation of the vagina and/or cervix at the time of the gynecological examination, other medical and clinical conditions that prevent the taking of a CS, condition after hysterectomy, already taken CS for the purpose of the present study, and hypersensitivity to the active substances or any excipient of the HPV vaccine
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06995157
Start Date
September 1 2023
End Date
April 1 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMC Ljubljana
Ljubljana, Občina Domžale, Slovenia, 1000